Skip to content

Study · Randomized controlled trial · 1999

2 results

The treatment of severe premenstrual syndrome with goserelin with and without 'add-back' estrogen therapy: a placebo-controlled study.

Leather AT, Studd JW, Watson NR, Holland EF

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology1 Feb 1999Cited by 36 (Europe PMC)

PMID10368798 (opens in a new tab)DOI10.1080/09513599909167531 (opens in a new tab)PepBankPUB-10368798
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with premenstrual syndrome, goserelin improved symptom scores at 2, 4 and 6 months versus placebo.

    In plain wordsIn women with premenstrual syndrome, goserelin improved symptom scores at 2, 4 and 6 months versus placebo.

    Peptide
    Goserelin
    Outcome
    Direction not reportedPremenstrual syndrome score
    Study

    n: not reported in source

    Comparator
    Placebo implant plus placebo tablets
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.6 mg four weekly · implant · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a significant improvement in PMS scores in Group C (Zoladex + placebo) after 2, 4 and 6 months of treatment when compared to pretreatment values and Group A (placebo + placebo).
    2 context sentences
    Summary · context
    In a double-blind placebo-controlled study in a specialist premenstrual syndrome clinic setting, 60 women aged between 20 and 45 years were randomized to one of three treatment groups: Group A (placebo implant four weekly + placebo tablets daily)
    Summary · context
    or Group C (goserelin 3.6 mg implant four weekly + placebo tablets daily).
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with premenstrual syndrome, goserelin improved symptom scores at 2, 4 and 6 months versus pretreatment.

    In plain wordsIn women with premenstrual syndrome, goserelin improved symptom scores at 2, 4 and 6 months versus pretreatment.

    Peptide
    Goserelin
    Outcome
    Direction not reportedPremenstrual syndrome score
    Study

    n: not reported in source

    Comparator
    Pretreatment
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.6 mg four weekly · implant · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a significant improvement in PMS scores in Group C (Zoladex + placebo) after 2, 4 and 6 months of treatment when compared to pretreatment values and Group A (placebo + placebo).
    2 context sentences
    Summary · context
    In a double-blind placebo-controlled study in a specialist premenstrual syndrome clinic setting, 60 women aged between 20 and 45 years were randomized to one of three treatment groups: Group A (placebo implant four weekly + placebo tablets daily)
    Summary · context
    or Group C (goserelin 3.6 mg implant four weekly + placebo tablets daily).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.